Bulletin of the American Physical Society
APS March Meeting 2017
Volume 62, Number 4
Monday–Friday, March 13–17, 2017; New Orleans, Louisiana
Session S21: Medical Physics Today and TomorrowInvited Undergraduate
|
Hide Abstracts |
Sponsoring Units: GMED Room: 281-282 |
Thursday, March 16, 2017 11:15AM - 11:51AM |
S21.00001: The Fundamental Role of Darwinian Dynamics in Cancer Invited Speaker: Robert Gatenby |
Thursday, March 16, 2017 11:51AM - 12:27PM |
S21.00002: Attacking cancer dormacy using game theory Invited Speaker: Robert Austin Here is the problem: Cancer kills primarily by re-emergence from a period of dormancy after initial treatment. The presence of driver mutations and subsequent clonal expansion by Darwinian evolution does not explain dormancy and re-emergence of cancer from a community of cancer and host cells (including stromal and immune cells), nor does it explain our inability to predict the emergence of metastasis, by far the real killer in cancer. Dormancy appears to be a slow-driven, multi-cell interaction-dominated, threshold system with a poor prognosis once the cancer emerges from dormancy. The mission here is to try and model the phenomena of dormancy using game theory ideas, and in {\em an in vitro} complex ecology designed to emulate the true complexity of an {\em in vivo tumor}. [Preview Abstract] |
Thursday, March 16, 2017 12:27PM - 1:03PM |
S21.00003: Advancing Cancer Treatment Delivery - Role of Physics Invited Speaker: Thomas Bortfeld Radiation treatment of localized tumors has evolved rapidly in recent decades, allowing radiation oncologists to deliver more focused treatments with significantly reduced side effects. One of the disruptive innovations led by physicists has been the development of intensity-modulated and image-guided radiation therapy (IMRT and IGRT), which has become the state of the art in radiation therapy with photons. At the next stage of the development, there is now growing interest in treating tumors with protons or heavier particles, which have the added physical benefit of the Bragg peak. However, proton and heavier particle therapy is available to fewer than 1{\%} of the patients. The first reason for that is the higher cost and bigger size of particle therapy facilities. The second reason is uncertainty of the treatment delivery, which limits its accuracy and precision. To address the first point (higher cost), physicists are involved in developments to make the equipment much more compact and cheaper. Examples include superconducting accelerators, laser-accelerated accelerators, more compact ``gantries'' that rotate the beam around the patient, as well as other solutions to treat the patients form multiple directions of incidence. The uncertainties in positioning the Bragg peak in the patient are being addressed by in-vivo measurements of dose deposition, or surrogates thereof. Examples include the measurement of prompt gamma radiation produced by the proton beam as it traverses the patient. Positron-Emission-Tomography (PET) scans have also been used to measure the tissue activation by the proton beam. Finally, the measurement of sound waves produced by pulsed proton beams leading to rapid expansions of the irradiated tissue has recently been successfully pursued. After resolving the issue of aiming a treatment beam with high precision and low cost, such that the majority of the patients will benefit from it, one of the next challenges for physicists in medicine is to better identify the actual target of the treatment, and the dynamics of treating it optimally in a multi-modality approach. [Preview Abstract] |
Thursday, March 16, 2017 1:03PM - 1:39PM |
S21.00004: Implications of Tumor Heterogeneity for Precision Medicine Invited Speaker: Robert Jeraj Medical physics is intimately connected with medicine, and is progressing along a similar path. General trend of medicine, particularly oncology, towards personalized treatment gave rise to precision medicine, which addresses the highly complex nature of disease. However, there are severe obstacles to overcome. For example, cancers evolve in time to become harder targets to treat. Understanding treatment resistance, and its development, often connected with the highly heterogeneous nature of the disease, is another key obstacle. Use of multi-modality imaging techniques such as molecular imaging is one of the solutions that medical physics can offer. Examples from clinical trials utilizing advanced molecular imaging, highlighting intra-tumor and inter-tumor heterogeneity will be presented. New understanding of cancer treatment response dynamics will be outlined. Potential for improved patient treatment designs steaming from these novel insights will be discussed. [Preview Abstract] |
Follow Us |
Engage
Become an APS Member |
My APS
Renew Membership |
Information for |
About APSThe American Physical Society (APS) is a non-profit membership organization working to advance the knowledge of physics. |
© 2024 American Physical Society
| All rights reserved | Terms of Use
| Contact Us
Headquarters
1 Physics Ellipse, College Park, MD 20740-3844
(301) 209-3200
Editorial Office
100 Motor Pkwy, Suite 110, Hauppauge, NY 11788
(631) 591-4000
Office of Public Affairs
529 14th St NW, Suite 1050, Washington, D.C. 20045-2001
(202) 662-8700